A fast track for a hard leukemia: US regulators give a targeted pill breakthrough status

Some leukemias carry a rearrangement in a gene called KMT2A that makes them especially hard to treat, and when the disease comes back after treatment, options narrow fast. Enzomenib, an oral drug from Sumitomo Pharma America, is designed to block the menin-KMT2A interaction that helps these cancer cells keep growing. On October 26, the US Food and Drug Administration granted it Breakthrough Therapy Designation for adults with relapsed or refractory KMT2A-rearranged acute leukemia — a status the FDA reserves for medicines showing early evidence of substantial improvement, and which speeds up development and review. The drug is being tested in the registrational Horizen-1 study and in combination trials. A designation is not an approval, and the evidence is still being gathered; but for patients whose leukemia has returned, a faster, priority path through the system is itself meaningful news — time is the scarcest thing they have.

SDG 3 · Good health and well-being — Mechanism: tech innovation